3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Stomach Neoplasms
3
Breast Neoplasms
3
Endometrial Neoplasms
2
Thyroid Neoplasms
1
Thyroid Diseases
1
Thoracic Neoplasms
1
Rectal Neoplasms
1
Peritoneal Neoplasms
1
Parathyroid Diseases
1
Ovarian Neoplasms
1
Neovascularization, Pathologic
1
Neoplasms by Site
1
Neoplasms
1
Lymphedema
1
Lung Neoplasms
1
Lung Diseases
1
Hypoparathyroidism
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Diseases
1
Carcinoma, Hepatocellular
1
Adenoma
1
Interventions
Carboplatin
4
Pemetrexed
3
pembrolizumab
2
patritumab
2
osimertinib
2
Sunitinib
2
Standard of Care
2
Paclitaxel
2
Irinotecan
2
Cisplatin
2
Ascorbic Acid
2
valrubicin
1
pralsetinib
1
palbociclib
1
napabucasin
1
linifanib
1
genexol-PM
1
dostarlimab
1
alectinib
1
Watchful Waiting
1
Sorafenib
1
Ramucirumab
1
Patient Reported Outcome Measures
1
Mitomycin
1
KRN-330
1
Interleukin-2
1
Indocyanine Green
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Gemcitabine
1
Erlotinib Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Neoplasms by Site
×
Indocyanine Green
×
Clear all
NCT02111824
2021-09-17
MIMIG
The Methodist Hospital Research Institute
Phase 1
Terminated
7 enrolled